Senate Committee Handles Bancel with Kid Gloves

Theater with Moderna Billionaire CEO Stephane Bancel Fails to Ask Key Questions

By Peter A. McCullough, MD, MPH

In 2006, Stephane Bancel was a sales director then head of Belgium operations for Eli Lilly, a mid to high level big pharma sales executive. In 2007 he catapulted to become CEO of French diagnostics company BioMérieux and began work with the Chinese to build the biosecurity annex level 4 at the Wuhan Institute of Virology. His company trained the Chinese lab technicians. Bancel then joined startup Moderna in 2011. Moderna’s has three patents that claim priority to applications filed between 2011 and 2016 covering its foundational intellectual property on mRNA, code to SARS-CoV-2 Spike protein, and related functions. In April 2020, Moderna’s sales and stock price skyrocketed on the promise of a COVID-19 vaccine that was planned for years. Bancel's stake of the company is about 9% and net worth estimated to be ~$6 billion.

While the countenance Senator Rand Paul was stern and his questions on the surface appeared intimidating, he and the committee failed to drill Bancel on issues that would reveal corruption, racketeering, fraud, conspiracy to commit domestic terrorism, public harm, or mass negligent homicide.

Here are five question sets the Senators either didn’t have the foundational understanding, perceptiveness, or courage to ask:

1. What was Bancel’s involvement with the Chinese in the construction of the lab annex? Was it intended for bioterrorism? How many times did Bancel visit the lab between 2007 and 2020?

2. Did Moderna collaborate with or rely upon Dr. Ralph Baric’s NIH work on chimeric SARS-CoV-2 as published in 2015 in Nature Medicine and the Proceedings of the National Academy of Science? Is the patented genetic code for Moderna mRNA derived from Baric’s chimeric virus or another one originating from the WIV BSL-4?

3. Did Bancel know ahead of time his product would cause myocarditis, neurologic injury, blood clotting, and immunologic syndromes (VITT, MIS)?

4. How many deaths and serious adverse events did Moderna record in its 90 day obligatory post-release safety data? Why has this dossier not been released to the public? When will it be? Assuming Moderna’s dossier has similar numbers of fatalities to Pfizer, why did Moderna fail to pull their product off the market early in 2021 due to excess risk of death?

5. Has Moderna or FDA or any third party at any time inspect its mRNA-1273 vaccine for quality, purity, and concentration as it is being produced by biodefense contractor National Resilience or other supplier? How does Moderna assure the quantity of mRNA in the final fill and finish of the vials before they are shipped to pharmacies and vaccine centers?

In conclusion, the Senate Committee on Health, Education, Labor and Pensions needs to step up its game if America wants to get to the bottom of what is going on with the COVID-19 vaccine debacle. I suggest they call in some doctors with courage, expertise, and clear vision to advise them on questioning. Wednesday March 22, 2023 fell short by a Kentucky mile and Bancel must be skipping away in relief.

If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Leake JS, McCullough PA. Courage to Face COVID-19: Preventing Hospital Deaths While Battling the Biopharmaceutical Complex

Menachery VD, Yount BL Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015 Dec;21(12):1508-13. doi: 10.1038/nm.3985. Epub 2015 Nov 9. Erratum in: Nat Med. 2016 Apr;22(4):446. Erratum in: Nat Med. 2020 Jul;26(7):1146. PMID: 26552008; PMCID: PMC4797993.

Menachery VD, Yount BL Jr, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J, Sheahan TP, Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA, Baric RS. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53. doi: 10.1073/pnas.1517719113. Epub 2016 Mar 14. PMID: 26976607; PMCID: PMC4801244.

Aquino-Jarquin G. The patent dispute over the breakthrough mRNA technology. Front Bioeng Biotechnol. 2022 Nov 3;10:1049873. doi: 10.3389/fbioe.2022.1049873. PMID: 36406223; PMCID: PMC9669595.